Page 18 - Fady Boctor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales

Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Exchange commissionCompany nasdaqCompany board of directorsPetros pharmaceuticalsSecurities exchangePetros pharmaceuticals incMetuchen pharmaceuticalsQuarter highlightsFady boctorPetros pharmaceutical presidentChief commercialPrescription medicinesMedical devicesVacuum erection devicesMedical deviceSecurities act

Petros Pharmaceuticals Welcomes Dr Mohit Khera to Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil)

Share this article Share this article NEW YORK, Feb. 18, 2021 /PRNewswire/ Petros Pharmaceuticals, Inc. ( Petros or the Company ) (NASDAQ: PTPI), a leading provider of therapeutics for men s health, today announces that Mohit Khera, M.D., M.B.A., M.P.H. has joined the company s steering committee to develop expanded patient access initiatives for STENDRA® (avanafil) product, an oral medication used in the treatment of erectile dysfunction (ED). Mohit Khera, M.D., M.B.A., M.P.H., specializes in male infertility, male and female sexual dysfunction, and testosterone replacement therapy. Dr. Khera has dedicated his clinical and research efforts to three main areas: testosterone, erectile dysfunction, and Peyronie s disease. Soon after completing my fellowship he started the Laboratory for Andrology Research. His laboratory focuses on basic science research on testosterone and its effects on the prostate, stem cells to treat erectile dysfunction, the effects of finasteride

United statesMohit kheraMaster in public healthEndo pharmaceuticalsPetros pharmaceuticalsBoston universityMaster in business administrationExchange commissionMen health for the houston chronicle newspaperHealth program at baylorPrnewswire petros pharmaceuticals incPetros pharmaceuticals incSecurities exchangeAuxilium pharmaceuticalsLaboratory for andrology researchVanderbilt university

Petros Pharmaceuticals Establishes Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil)

Share this article Share this article NEW YORK, Feb. 4, 2021 /PRNewswire/ Petros Pharmaceuticals, Inc. (Petros or the Company) (Nasdaq: PTPI), a leading provider of therapeutics for men s health, today announced that it has formed a steering committee to develop expanded patient access initiatives, including non-prescription or Over the Counter (OTC) status strategies, for its STENDRA® (avanafil) product, an oral medication used in the treatment of erectile dysfunction (ED). The committee will build upon more than 2 years of work conducted by the Company to pursue direct to consumer self-care mechanisms for increased engagement and control over their erectile health. The initial members of the steering committee include Greg Bradley, member of the Petros board of directors and president and CEO of Foundation Consumer Healthcare, which has an industry leading portfolio of differentiated OTC products, including the #1 OB-GYN recommended Plan B One-Step emergency contraception,

United kingdomPaul wardleTania kingGreg bradleyFoundation consumer healthcareEndo pharmaceuticalsCompany nasdaqPetros pharmaceuticalsExchange commissionPetros pharmaceuticals incSecurities exchangeAuxilium pharmaceuticalsBeacon associatesPlanb one stepFady boctorChief commercial officer